ACC.23 Program Chair Doug Drachman, MD, explains what he saw as some of the key takeaways from the American College of Cardiology (ACC) 2023 annual meeting.

Researchers examined data from more than 700 TAVR patients, publishing their findings in the American Journal of Cardiology.

The veteran interventional cardiologist told Cardiovascular Business he sees potential in the ACC's ability to grow both nationally and internationally in the next year. 

Catch up on the biggest news that came out of the second day of ACC.23 in New Orleans. 

The conference kicked off with three late-breaking studies that could have a huge impact on patient care going forward. 

As much as TAVR's popularity has grown in recent years, there are still many instances when a heart team may find that surgery offers the best path forward. 

Both vendors used the four-day conference as an opportunity to provide key updates about their TAVR valves.

Early SVD has been reported in these devices, particularly three to four years after implantation. According to the FDA, this has resulted in surgical replacement procedures and transcatheter valve-in-valve interventions. In some cases, the patient died.